Electromed, Inc. (ELMD) Earnings Call Transcript
August 25, 2026
Earnings Call Speaker Segments
Good afternoon, everyone, and thanks for being with us on the Electromed earnings call. Earlier today, Electromed Inc. published the financial results it recorded for the fourth quarter of fiscal 2026. You can access that press release at this moment on the company's website, www.smartvest.com. Before we get started, I'd like to remind all of you that some of what management says today falls under the category of forward-looking statements — this includes remarks about the company's operating and financial results and plans for the future. Such statements carry risks and uncertainties, and those factors might lead actual performance or achievements to differ materially from what has been projected. All of these statements reflect management's expectations as of today's date. Don't rely too heavily on those forward-looking statements. The company isn't obligated to update or revise them, whether because of new information, future events, or anything else. For more guidance on this, please see the company's SEC filings. With me today are Jim Cunniff, Electromed's President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer. As we've done on earlier calls, Jim will go over operational highlights from the quarter. After that, Brad will walk through the financials, and then we'll wrap up with a question-and-answer session. So with that, I'll hand the call over to Jim Cunniff, President and Chief Executive Officer of Electromed.
Thanks, Mike, and thanks to everyone for being with us today. I'm happy to share that Electromed has posted another record quarter. With Q4, we've now achieved 15 quarters in a row of revenue and profit growth on a year-over-year basis, and that record shows how durable our direct-to-patient model is and how SmartVest is gaining greater recognition among the bronchiectasis community. Fourth-quarter net revenue reached a record $19.4 million, an increase of 12% compared with the fourth quarter of last year, and once again we generated operating leverage during the quarter. Operating income came to $3.8 million in Q4, which represents 26% growth year over year. Fully diluted earnings came in at $0.39 a share, which was also a quarterly record for us. Growth during the period was paced by our core home care channel, up 15%, and our distributor channel rose 2%, with steady SmartVest demand evident in both. Revenue from hospitals dropped 29% in the quarter. As we've noted previously on these calls, orders from hospitals take longer to close and are by nature harder to forecast than what we see in our other channels. Our hospital business still looks promising to us as a gateway into the home, and we'll continue putting investment behind that part of the business. We ended the quarter with 64 direct sales representatives, up 6 reps from the third quarter. That rise is tied to bringing people on board in advance of the territory expansions we have slated for fiscal 2027, and the quality of talent we've managed to bring into the team has us feeling good; we're still growing our sales force in a measured way, and the revenue growth this team has produced continues to impress me. As a lot of you are aware, the largest strategic opportunity for Electromed sits in the underserved bronchiectasis market. Right now, about 1 million patients across the United States carry a bronchiectasis diagnosis, yet only around 16% of them are seeing benefit today from high-frequency chest wall oscillation therapy. That means roughly 800,000 patients have a bronchiectasis diagnosis and might benefit from SmartVest but haven't been prescribed therapy. We also believe there could be over 4 million more people living with bronchiectasis who haven't been diagnosed yet. That really highlights both the size of the market opportunity and the importance of doing more to educate patients and providers. So to tackle that, we introduced our triple down on bronchiectasis campaign last year. Its goal is to build awareness of our therapy and to emphasize how essential airway clearance is when it comes to treating bronchiectasis. The campaign centers on our three-part approach to treatment. First, clear the airways using SmartVest to get rid of the mucus that leads to future infections; second, address the infection with antibiotics; and third, bring down inflammation. Taken as a whole, those 3 measures aim to interrupt the loop of chronic infection, ongoing inflammation, and airway damage—the forces behind worsening lung disease and a lower quality of life for such patients. During this year we broadened the effort through a fresh program titled Treat Smart from the start, meant to assist clinicians in spotting patients for whom existing airway clearance therapy is failing and in judging when treatment should be reconsidered. Beyond those programs, our clinical group remained active this quarter building provider awareness; we delivered presentations at 2 regional respiratory conferences, reaching a combined audience of over 200 clinicians. We also ran 3 peer-to-peer webinars this quarter, each drawing at least 100 clinicians, and attended several national conferences. On the research front, we finished a manuscript, and it was accepted for publication in the September issue of the COPD Foundation Journal. Drawing on data from the NTM Bronchiectasis Research Registry, the study showed that 58% of qualified patients were not prescribed HFCWO therapy even though they met all the clinical criteria required for insurance coverage. That gap is meaningful, and we are addressing it by engaging physicians who diagnose high volumes of bronchiectasis patients yet are not prescribing HFCWO therapy so far. In addition, the BE NTM Association has introduced a fresh educational site aimed at physicians and patients, featuring a quick guide covering airway clearance. Sponsoring their airway clearance resource library is something we take pride in, since it helps fill the gap in education for both patients and providers. I've previously discussed our smart order e-prescribe solution, which is transforming the way prescribing clinics send orders more efficiently to our fulfillment team. Notably, the Centers for Medicare and Medicaid Services has finalized its administrative simplification rule, adopting new standards for electronic signatures and health care claims attachment transactions; practically speaking, this means covered entities must modernize their order processing and eliminate faxes by May of 2028. Our electronic prescribing product is already compliant with CMS rules on e-signatures and order handling, so we're in a strong spot as the sector shifts away from fax. During Q4, Smart Order accounted for over 45% of incoming orders, and those shipments went out roughly 5 days sooner than faxed ones. Broadening payer coverage is still central to our strategy, since that's ultimately how patients who need it get SmartVest; we closed the year with contracts covering 87% of U.S. covered lives. Our market access team pulled off something really impressive—they closed out the year with 40 new payer contracts signed and grew our network by over 6 million covered lives. Another point of pride for me is that Electromed's products are made right here in the United States. With all the supply chain turmoil the industry has faced, we see our domestic operations as a real competitive edge. Domestic sales account for 99% of our net revenue, and that focus is what makes us confident we can keep up our strong history of delivering on time and holding gross margins at mid-70% or better. I'd also like to give a shout-out to the Electromed team, who keep performing at a high level. Just recently, the Minneapolis St. The Paul Business Journal ranked Electromed as Minnesota's eighth fastest-growing public company, and the Star Tribune honored us as a top workplace in Minnesota this year. During fiscal 2026, employee referrals accounted for 45% of our new hires. Our team members are engaged and enthusiastic about recruiting people like themselves into the organization. In our view, engaged employees lead to engaged customers, and that virtuous cycle has been central to building this business. Before I turn the call over to Brad, I'd like to briefly address a significant leadership change we also announced today. After considerable reflection and discussions with our Board, I have chosen to step down as Electromed's Chief Executive Officer, with the anticipated date being April 2027. Our Board is conducting a careful succession planning effort alongside this move, and I am confident the timing will be appropriate both for the company and for me personally. I take great pride in what our team has accomplished during the last 3 years. We have built a robust business, established a well-defined growth strategy and, above all, cultivated a capable leadership team that gives me great confidence in what lies ahead for the company. For the rest of my time leading this company until I retire, my attention will remain fixed on the same priorities it has always had: carrying out our strategy, meeting what we have promised shareholders, and making sure the leadership handover goes smoothly. My confidence in how strong this organization is, and in the opportunities ahead of it, has never been greater. I want to thank our employees, customers, shareholders and Board for giving me the opportunity to lead this company, and I am eager to keep working alongside the team during the months ahead. With that, I'll turn things over to you, Brad.
Thanks, Jim. Working alongside you and seeing how you've led the Electromed team during the past few years has been a real pleasure, and I'm eager to keep collaborating with you right up to when you retire. Now to the financial results. Every figure I'm going to walk through covers the 12 months that ended June 30, 2026, which I'll call fiscal 2026, and is measured against the 12 months that ended June 30, 2025, or fiscal 2025, unless I say otherwise. Q4 net revenues rose 11.6% to $19.4 million, which lifted net revenues for our full fiscal year 2026 to a record $73.8 million, a gain of 15.3% over $64 million last year. In our direct home care market, annual revenues climbed 16.3% year-over-year to $66.6 million, up from $57.3 million in the prior year. That revenue increase came from more direct sales representatives, greater productivity among those representatives and higher net revenues per approval. For fiscal year 2026, annualized home care revenue per weighted average direct sales representative reached $1,145,000, which is above Electromed's target range of $1 million to $1,100,000 per rep. Given how strongly we performed in fiscal 2026 and the continued efficiency we expect in fiscal 2027, we are raising our target range for fiscal year 2027 home care revenue per rep to $1,050,000 to $1,150,000, as we weigh the record sales rep productivity from fiscal 2026 against the sales team expansion we have planned for fiscal 2027. Our non-home care business saw revenue grow 6.7% to $7.2 million in fiscal 2026. That gain came mainly from higher distributor and hospital revenue, which rose 12.7% and 9.6%, respectively. Gross profit climbed to $57.9 million, or 78.5% of net revenues, from $50 million, or 78.1% of net revenues, in fiscal 2025. Higher revenue and greater net revenue per device were the main drivers behind the rise in both gross profit and gross margin. Selling, general and administrative, or SG&A, expenses came to $42.7 million, up $3.4 million, or 8.7%, from $39.3 million. That increase stemmed chiefly from higher salaries and incentive compensation tied to a larger average headcount across the sales, sales support, marketing and reimbursement teams, which allows us to process more patient referrals. Operating income for this year was $13.9 million, or 18.8% of net revenues, versus $9.7 million, or 15.1% of net revenues, last year. Operating income growth of 43.7% shows the leverage we get from mid-teen growth in net revenues and gross profit, offset by disciplined investment in the business's operating expenses, which rose roughly 9%. Taken together, these full year results leave us excited to have delivered a record year, with pretax income of $14.4 million, net income of $11.3 million and full year EPS of $1.30 per diluted share. At June 30, 2026, Electromed held $20.5 million in cash and $29.8 million in accounts receivable with no debt, reaching working capital of $45.1 million and total shareholders' equity of $54 million. The cash balance shows a $5.2 million rise for the year that ended June 30, 2026, versus a $0.8 million cash decline during the same period a year earlier. Positive operating cash flow of $9.7 million mainly drove that cash increase across the 12 months ended June 30, 2026, partly offset by $3.9 million in repurchases of Electromed common stock. To wrap up, Jim and I feel very encouraged by the dedication and energy the Electromed team shows as we keep delivering our innovative SmartVest technology to patient populations that remain significantly underserved; it's rewarding to see how that commitment to the patients and physicians we serve has turned into strong financial performance throughout fiscal 2026, creating meaningful value for Electromed and our shareholders. Looking ahead into fiscal 2027, we still see opportunity to build on the investments we've made to push both our mission and our financial commitments forward, delivering double-digit top line growth, expanded operating leverage and strong operating cash flow in the new year. Operator, please open the call to questions.
But before we get started, Jim, congratulations on retiring next year — we're wishing you all the best.
Thanks, Kyle. I really appreciate that.
Yeah. Good to see we've got a bit of time for the transition. So I appreciate the update. And perhaps for my first question, clearly, another very strong quarter on operating leverage, and you touched on that somewhat. But could you perhaps talk a little about what you expect for continued leverage in fiscal '27? And any plans to bring on additional reps in territories too?
Well, I think Brad put it well, we expect this year won't necessarily be a repeat of last fiscal year, but we definitely project that we'll deliver double-digit top line growth along with operating leverage. That's the mantra we've been pounding the drum on for 3 years now, and we've managed to deliver on it. So yes, we're confident we can do that; we've brought on sales reps, which excites us. So as you heard in the prepared remarks, we finished the year with 64 direct sales reps. Quite a few of them actually joined in June of the last fiscal year. But the good news is they were meant to help fill the gap for territory expansions we have for this fiscal year; so we're essentially hitting the ground running. That includes 2 hospital account liaisons, actually; these are people we're running a pilot with in a couple of key markets to see whether we can capture some of those patients who are in the hospital and then get transitioned to the home and secure those referrals; beyond that, we also have 3 more territories that we're looking to fill; so touch wood, our expectation is to have 67 territories filled this year, including 2 hospital account liaisons. Brad also noted in his comments that we've raised our guidance on revenue per rep for this year, even though it's below where we ended up last year. And that's mainly because, as you know, Kyle, some of these reps will need some time to ramp up and become productive for us. But yes, we're really bullish on the business and the new talent we're bringing onto the team.
Understood. Thanks for that. And as a follow-up, the cash balance keeps rising while the share price has been really strong. What are your thoughts on capital allocation and how you plan to put that cash to work from here?
Thanks for asking, Kyle. The strategy hasn't changed. We still view our cash through a set of priorities. Number one is simply reducing risk in the business. Number two is putting money back into the business. As Jim said, we're bringing on a good number of sales reps as we head into 2027, and we want to back them up, not only on headcount but also with the proper marketing support and the proper investment in R&D, so we keep reinvesting in the business as much as we can while still delivering leveraged growth across the P&L. Past that, we'll keep looking for ways to build shareholder value, just as we've done before. Our primary approach there has been share repurchases, and we've carried those out over the last couple of years. So when the opportunity presents itself, we'll keep finding ways to create that shareholder value.
Before I ask my questions, congrats on the announcement. Three years and 15 straight quarters is a solid point to hand things off from; so thanks for taking my question.
I appreciate the kind words.
My first question is about R&D. As a percentage, spending went up significantly versus the same period last year. Even so, it remains a minor line on the P&L. Can you help us understand what that dollar figure actually represents, whether right now or going forward? Is it refinement of the Clearway generator? Is it on the connectivity and data side—things such as smart nodes? Or does it involve effort on something adjacent to the existing platform?
Great question. And as you note, our R&D investment really sits on a very small base. Since we only have one product, our R&D spending really splits into two parts for maintaining the current technology. We're constantly seeking ways to improve what we already offer—that's one component, and we're putting money into it. The second component is innovation. I believe I've brought this up on earlier calls. One area where we feel we could use more innovation is—well, there are actually two areas. The first is connectivity, which we're actively addressing, as you noted. The second is simply broadening our vest line. That’s why a major focus for our R&D group is boosting and broadening that capability, mainly in the smaller vest sizes.
Great. There's one more thing I want to ask about. The deck lists acquisition among the three key pillars of the growth strategy. I'd like to get into the details of that. When you talk about inorganic opportunities, which problem are you trying to address? Does it mean bringing in a second product that the reps already carry? Or does it mean buying a capability like monitoring data? Or is diversification the point?
Yes, it could be any of those. No, I think those are excellent questions. We're constantly evaluating this — as a company built around just one product, it would be ideal if we could give our sales reps another leg to the stool, put something in their bag that pairs well with the call point they concentrate on and strengthens the customer relationship. We're always watching for situations where 1 plus 1 equals 3; that's what interests us. We simply haven't come across it so far. And regarding your question, we aren't limiting ourselves to a single inorganic opportunity. If it works for our sales rep and complements what they're already doing, we're very much open to that. On the other side, we have an outstanding reimbursement team and contracting engine. Within home care, that capability carries real worth. It’s another place where we might use it by acquiring a company and adding a team whose technology suits this market but who lack that kind of capability themselves.
I'm genuinely thrilled about how things turned out.
Thanks a lot.
First thing I want to get into is payer mix as we head toward fiscal 2027. It seems commercial dropped by a couple of few hundred basis points during fiscal '26. Part of that is likely comps, while Medicare and Medicare Advantage ticked up slightly. How should we view that trajectory? Is it simply going to bounce around? Are there underlying trends pushing things toward one side or the other?
Yes. No, first of all, I appreciate the question, Ben, and appreciate you joining the call. As you're aware, when we walk into a clinic and speak with a physician, we aren't determining which payer type the patient carries. What we're actually seeking is whether there are patients who could benefit from our technology. So from that standpoint, it's essentially a black box for us. We truly don't learn what kind of insurance that patient has until a prescription has been written. So typically and historically, the split has been fairly even between Medicare and commercial pay. I think the good news, and one of the points we want to emphasize, is that during the last fiscal year we added 6 million additional covered lives. So previously, we might have gotten a prescription; we may have been out of network, and we can't fulfill it because the patient doesn't want to be burdened with a large out-of-pocket expense. And so by continuing to add payer coverage, it simply helps our ability to serve our patients and our ability to no longer be out of network.
All right, so aside from demographics, maybe there isn't really a clear trend?
No. What I'd say is, the reality comes down to that stat, right? Roughly 10,000 people each day reach age 65. That pushes things more in the direction of Medicare. Still, if we look back across the last 3 years, the split between Medicare and commercial pay has stayed essentially 50 to 50.
Sure, that makes sense. Then second, regarding the CHEST guidelines—my understanding is they came out fairly recently and list HFCWO more or less across the board. What does that mean for your reps when they're detailing <<inaudible>>? Could you give us a sense of how that assists folks?
Yes. The good news, I think, is that the United States has never had care guidelines for treating bronchiectasis patients. And honestly, those guidelines will be published later this quarter. So that's something we're excited about. As you know, Ben, it's been on the horizon for quite a while. And it isn't as clear-cut as we'd hope. There really isn't an algorithm for how to treat bronchiectasis patients. What the guidelines essentially highlight is the various tools a provider can draw on when caring for someone with bronchiectasis. That list includes airway clearance—no shock there. And as you heard in my remarks, these patients face a chronic, irreversible condition; fluid accumulates in their lungs, and they require something to clear out that mucus, which serves as fuel for subsequent infections. So we're sort of the first line of attack. One more item worth highlighting is genuinely encouraging: alongside the CHEST guidelines, the bronchiectasis and NTM Foundation has just rolled out a fresh BE care pathway. My sense is this will make it somewhat easier for health care providers to grasp which tools are available to them when treating bronchiectasis patients. So that's positive for the industry overall, and positive for us too, since airway clearance appears in both sets of guidelines.
Congratulations on the retirement, and topping it off.
Yeah, I really appreciate that, Ben. Thanks a lot.
Yes, thank you, operator. And just before we wrap up the call, I'd like to leave everyone with a few main points from the quarter we just finished. To begin with, this marked our 15th quarter in a row of growth in both revenue and profit compared with the same period a year earlier, with record revenue and record diluted earnings per share; delivering ongoing growth and profitability is what we're aiming for. Consistent with that aim, we are putting investment in ahead of demand, for example by expanding our sales force. The opportunity in bronchiectasis is still a substantial one, and our Treat Smart from the Start campaign, along with our clinical, educational and payer initiatives, is all built to help us responsibly reach more patients. Our financial base is solid; our balance sheet carries no debt and we generate strong cash, and that lets us continue investing in profitable growth. As ever, I appreciate your joining us today. Should you have questions or want to arrange a call with the Electromed team following today's report, you can reach our Investor Relations partners at ICR Healthcare. Operator, please close the call.
That brings us to the end of today's teleconference. You can go ahead and disconnect your lines now. Thanks for joining us.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Electromed, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Electromed, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.